XRAY

Rating neutralAI Memo

DENTSPLY SIRONA

As of 2026-09-11/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Baird conference offers a near-term strategy checkpoint • 2026-09-15

Base target: $12 / p=50% prob

Biggest risk

The margin improvement did not prevent a 6.3% constant-currency sales decline, with particularly severe weakness in Orthodontic and Implant Solutions. The recovery remains execution-dependent, and no post-print analyst revision evidence is available in the packet.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Q2 adjusted EBITDA margin improved to 21.3%, operating cash flow rose to $99 million, free cash flow reached $55 million, and management maintained its 2026 sales and adjusted-EPS outlook. Distribution expansion and connected-dentistry adoption could eventually translate into better revenue performance.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-11

Base target

$12

p=50%

Bull target

$16

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Sales contraction remains the principal downside test
Distribution expansion could improve connected-technology access
Q2 adjusted EBITDA margin improved to 21.3%, operating cash flow rose to $99 million, free cash flow reached $55 million, and management maintained its 2026 sales and adjusted-EPS outlook.

BearKey bullets

Analyst estimate revisions, target changes, options positioning, and short-interest data are unavailable.
Continued constant-currency sales contraction, especially in Orthodontic and Implant Solutions.
Q2 operating cash flow benefited by approximately $44 million of tariff refunds, making part of the improvement nonrecurring.

WatchKey bullets

Baird conference offers a near-term strategy checkpoint

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $12 (p=50%)

Target spread vs base: +35% / -26%

Scenario probabilities

Bull Target: $16 (p=25%)Base Target: $12 (p=50%)Bear Target: $9 (p=25%)

Commentary

Primary-source evidence is mixed: Q2 margins and cash generation improved and full-year guidance was maintained, but reported and constant-currency sales declined. Several directors purchased shares near $9.89-$10.14 in June, a modest secondary confidence signal rather than evidence of operating improvement. Recent trusted analyst revisions and usable social, options, or short-interest signals are unavailable, supporting a monitoring stance rather than a directional call.

As of 2026-09-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Sales contraction remains the principal downside test
Distribution expansion could improve connected-technology access

Scenarios

Bull Target (Scenario probability)

$16 / p=25% prob

Base Target (Scenario probability)

$12 / p=50% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-15
Baird conference offers a near-term strategy checkpoint
Management is scheduled to present at the Baird Global Healthcare Conference on September 15, providing a near-term opportunity to clarify Return-to-Growth execution after Q2 results; no incremental guidance is assured. [#IR-2026-09-03]
Prob 35.00% • Move 3.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Sales contraction remains the principal downside test
2026-12-31
Q2 net sales fell 4.1% reported and 6.3% in constant currency, including a 14.9% constant-currency decline in Orthodontic and Implant Solutions. Failure to stabilize these trends would weaken the recovery thesis despite improved margins. [#SEC-8K-2026-08-06]
Prob 65% • Move -10% • Priced-in 60%

Long-term Catalysts

Months to a year

Distribution expansion could improve connected-technology access
2027-12-31
The expanded Medline Sinclair partnership broadens access to the Connected Technology Solutions portfolio in Canada. Combined with other 2026 dealer-network additions, commercialization progress could support recovery, but Q2 Connected Technology sales still declined 3.8% in constant currency. [#SEC-8K-2026-08-06]
Prob 45% • Move 12% • Priced-in 30%

Risks

Analyst estimate revisions, target changes, options positioning, and short-interest data are unavailable.
Continued constant-currency sales contraction, especially in Orthodontic and Implant Solutions.
Q2 operating cash flow benefited by approximately $44 million of tariff refunds, making part of the improvement nonrecurring.
Restructuring, transformation, impairment, and tax items could create material divergence between adjusted and GAAP results.
Return-to-Growth initiatives and expanded distribution may not produce timely end-demand improvement.

Peers

Symbol	Summary
ALGN	Relevant dental-technology comparison through clear aligners and digital workflows, although its product mix and growth drivers differ materially from XRAY's diversified equipment, consumables, implants, and healthcare portfolio.
HSIC	Useful dental-channel reference because it supplies dental practices with merchandise, equipment, and technology, but its distribution model is not directly comparable with XRAY's manufacturing economics.
ABT	Large diversified medtech benchmark useful for broad margin and execution context, but substantially larger and not a direct dental-products peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-11

Loading AI feed…

Symbol

Summary

ALGN

Relevant dental-technology comparison through clear aligners and digital workflows, although its product mix and growth drivers differ materially from XRAY's diversified equipment, consumables, implants, and healthcare portfolio.

HSIC

Useful dental-channel reference because it supplies dental practices with merchandise, equipment, and technology, but its distribution model is not directly comparable with XRAY's manufacturing economics.

ABT

Large diversified medtech benchmark useful for broad margin and execution context, but substantially larger and not a direct dental-products peer.